Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in frequently exacerbating COPD (METREX)
NCT02105948Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of mepolizumab in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Apr 2014; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02105948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105948.